EU antitrust regulators have fined nine drug makers a combined €146M for blocking the supply of cheaper drugs through "pay-for-delay" deals in which brand name companies pay generic manufacturers not to enter the market with their products. Denmark's Lundbeck (OTC:HLUKF) received the biggest penalty of €94M. The punishment highlights how authorities on both sides of the Atlantic are coming down on "pay for delay," with the U.S. Supreme Court recently ruling that the FTC can take action against such deals.